EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy

Maha S Al-Keilani iD, Samah Awad, Hanan M Hammouri, Tala Al Shalakhti iD, Basima A Almomani iD, Muna M Dahabreh, Mohammad-Jaafar Ajlony

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0284511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Maha S Al-Keilani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Research, Jordan University of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Objective monitoring of improvement during treatment of pulmonary exacerbation can be difficulty in children when pulmonary function testing cannot be obtained. Thus, the identification of predictive biomarkers to determine the efficacy of drug treatments is of high priority. The major aim of the current study was to investigate the serum levels of vasoactive intestinal peptide (VIP) and alpha calcitonin gene related peptide (aCGRP) of cystic fibrosis pediatric patients during pulmonary exacerbation and post-antibiotic therapy, and possible associations of their levels with different clinicopathological parameters.

Methods

21 patients with cystic fibrosis were recruited at onset of pulmonary exacerbation. Serum was collected at time of admission, three days post-antibiotic therapy, and two weeks post-antibiotic therapy (end of antibiotic therapy). Serum VIP and aCGRP levels were measured using ELISA.

Results

Overall least square means of serum aCGRP level but not VIP changed from time of exacerbation to completion of antibiotic therapy (p = 0.005). Serum VIP was significantly associated with the presence of diabetes mellitus (p = 0.026) and other comorbidities (p = 0.013), and with type of antibiotic therapy (p = 0.019). Serum aCGRP level was significantly associated with type of antibiotic therapy (p = 0.012) and positive Staphylococcus aureus microbiology test (p = 0.046).

Conclusion

This study could only show significant changes in serum aCGRP levels following treatment of pulmonary exacerbations. Future studies with larger sample size are required to investigate the clinical importance of VIP and aCGRP in cystic fibrosis patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansChildVasoactive Intestinal PeptideCalcitonin Gene-Related PeptidePilot ProjectsDisease ProgressionAnti-Bacterial Agents

Substanzen

Vasoactive Intestinal PeptideCalcitonin Gene-Related PeptideAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
  • Department of Pediatrics and Neonatology, College of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
  • Department of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
  • Department of Mathematics and Statistics, College of Science and Arts, Jordan University of Science and Technology, Irbid, Jordan.
  • Department of Respiratory Medicine, Royal London Hospital Barts NHS Trust, London, United Kingdom.
  • Department of Pediatrics, Princess Rahma Teaching Hospital, Irbid, Jordan.

ORCID-Profile: Maha S Al-Keilani, Tala Al Shalakhti, Basima A Almomani

Förderung

  • Deanship of Research, Jordan University of Science and Technology

Zitieren

APA

Al-Keilani, M. S., Awad, S., Hammouri, H. M., Al Shalakhti, T., Almomani, B. A., Dahabreh, M. M., & Ajlony, M. J. (2023). Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy. PLOS ONE. https://doi.org/10.1371/journal.pone.0284511

Vancouver

Al-Keilani MS, Awad S, Hammouri HM, Al Shalakhti T, Almomani BA, Dahabreh MM, et al. Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy. PLOS ONE. 2023. doi:10.1371/journal.pone.0284511

BibTeX
@article{AlKeilani2023,
  author = {Al-Keilani, Maha S and Awad, Samah and Hammouri, Hanan M and Al Shalakhti, Tala and Almomani, Basima A and Dahabreh, Muna M and Ajlony, Mohammad-Jaafar},
  title = {Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0284511}
}
Kostenlos starten →